ArticleBMJ open2026
Safety of laparoscopic surgery without No.253 lymph node dissection for mid and low rectal cancer (SMOOTH): study protocol for a phase III, multicentre randomised controlled trial in China.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06146946 (Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node, a Prospective, Multicenter, Non-inferior Randomized Controlled Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node, a Prospective, Multicenter, Non-inferior Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTotal mesorectal excision is currently the standard surgical treatment for rectal cancer; however, the optimal extent of proximal lymph node dissection remains a subject of ongoing debate. The No.253 lymph node is the third station node along the inferior mesenteric artery system. Whether dissection of this region is necessary for all cases of rectal cancer remains inconclusive. Our previous retrospective study demonstrated that the incidence of No.253 lymph node metastasis is extremely low in rectal patients without clinical high-risk factors. Based on these findings, we have designed a randomised controlled trial to evaluate the oncologic safety of omitting No.253 lymph node dissection in this specific patient population. METHODS AND ANALYSIS: This is a multicentre, randomised controlled clinical trial aimed at evaluating the safety of resection for rectal cancer without No.253 lymph node dissection. A total of 1384 patients with clinically confirmed low-risk rectal cancer will be enrolled. Participants will be randomly assigned to either the No. 253 lymph node dissection group or the non-dissection group. The primary endpoint is 3-year disease-free survival rate, with a pre-specified non-inferiority margin of 7%. Secondary endpoints include the total number of lymph nodes dissected, incidence of intraoperative and 30-day postoperative complications, intraoperative blood loss, operative time, postoperative hospital stay and 3-year overall survival (OS) rate. ETHICS AND DISSEMINATION: This study protocol has been approved by the Ethics Committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (reference no. 23/467-4210), and has been registered at ClinicalTrials.gov (NCT06146946). The findings of this trial will be disseminated through publication in peer-reviewed international medical journals. De-identified individual participant data will not be shared. TRIAL REGISTRATION NUMBER: NCT06146946.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.